. Author manuscript; available in PMC: 2021 Jul 30.

Published in final edited form as: Anticancer Res. 2017 Jun;37(6):2831–2838. doi: 10.21873/anticanres.11634

Table II.

Half maximal-inhibitory concentrations for trifluridine and mitogen-activated protein kinase kinase 162 (MEK162) and combination index (CI) for their combination for different human colorectal carcinoma cell lines. Data are the mean±SD.

Cell line	Trifluridine (μM)	MEK162 (μM)	CI^*
CaCO2 (KRAS/BRAF WT)	76.97±2.61	4.11±0.52	1.35
COLO 320HSR (KRAS/BRAF WT)	16.84±2.67	11.25±1.20	1.29
KM12 (KRAS/BRAF WT)	44.12±13.40	1.97±0.63	0.83
SNU-C1 (KRAS/BRAF WT)	44.76±3.12	0.043±0.019	0.04
HT29 (KRAS^V600E MT)	77.45±4.17	0.074±0.01	0.25
LS 174T (KRAS^G12D MT)	88.06±11.04	0.21±0.02	0.72
SW480 (KRAS^G12V MT)	66.28±12.09	1.88±0.37	0.51
HCT116 (KRAS^G13D MT)	34.26±5.65	1.21±0.20	0.75
DLD-1 (KRAS^G13DMT)	29.41±4.95	2.48±0.27	0.67

WT, Wild-type; MT, mutant.

Mean values at effective dose of 50%, 0.1-0.3: strong synergism, 0.3-0.7: synergism, and 0.7-0.9: slight synergism.